Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs

Abstract

Background Long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for treatment of type 2 diabetes (T2DM) in the United States, the European Union, and Japan. In our previous work, we designed and characterized a novel GLP-1 RA, SKL-18287. This RA consists of only natural L-amino acids, and is believed to exist in an oligomer form in systemic circulation. This unique feature may allow high biological stability and a long-lasting glucose lowering effect in T2DM treatment. In the present study, we investigated the pharmacokinetic properties of SKL-18287 in rats, monkeys, and mini-pigs. Tissue distributions of radioactivity were also studied in rats after subcutaneous administration of [³H]-SKL-18287.

Methods Plasma concentrations of SKL-18287 were measured by LC-MS/MS after intravenous and subcutaneous administration of SKL-18287 in rats, monkeys, and mini-pigs. Pharmacokinetic parameters were then calculated and compared among these animal species. Tissue concentrations of radioactivity were determined by liquid scintillation counting following sample combustion, after subcutaneous administration of [³H]-SKL-18287 to rats.

Results SKL-18287 showed an extended half-life of over 5 h, with good subcutaneous bioavailability, in all animal species. Prediction of the pharmacokinetic profiles of SKL-18287 in humans using an animal scale-up approach revealed an SKL-18287 half-life of 14.8 h. The radioactivity concentration in the pancreas, a target tissue of GLP-1RA, was relatively higher than in other tissues, until 12 h after [³H]-SKL-18287 administration.

Conclusion SKL-18287 might be sufficient to maintain an effective concentration for a once-daily treatment for T2DM, and is a unique GLP-1 RA with a pancreas-selective feature.

Key words

glucagon-like peptide-1 receptor agonist - Type 2 diabetes - pharmacokinetics - tissue distribution

• References

• 1 Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-711
• 2 Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913
• 3 Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705
• 4 Flint A, Raben A, Astrup A. et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520
• 5 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439
• 6 Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835
• 7 Plamboeck A, Holst JJ, Carr RD. et al. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005; 48: 1882-1890
• 8 Deacon CF, Pridal L, Klarskov L. et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271: E458-E464
• 9 Eng J, Kleinman WA, Singh L. et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405
• 10 Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997; 272: 4108-4115
• 11 Courtney H, Nayar R, Rajeswaran C. et al. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes Metab Syndr Obes 2017; 10: 79-87
• 12 Thompson AM, Trujillo JM. Dulaglutide: The newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother 2015; 49: 351-359
• 13 Plum A, Jensen LB, Kristensen JB. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis. J Pharm Sci 2013; 102: 2882-2888
• 14 Elbrønd B, Jakobsen G, Larsen S. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398-1404
• 15 Takeuchi M, Okamoto M, Okamoto R. et al. Discovery of a long-acting glucagon-like peptide-1 analog with enhanced aggregation propensity. Peptides 2018; 102: 8-15
• 16 Takeuchi M, Okamoto M, Watanabe N. Pharmacological evaluation of SKL-18287, a new long-acting glucagon-like peptide receptor agonist with enhanced aggregation propensity, in rodent models. Int J Pept Res Ther. 2018;
• 17 Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15: 1071-1121
• 18 Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 1983; 72: 1103-1127
• 19 Steensgaard D, Thomsen J, Knudsen L et al. The molecular basis for the delayed absorption of the once-daily human GLP-1 analog , liraglutide. Diabetes 2008; 57: A164
• 20 Wang Y, Lomakin A, Kanai S. et al. Transformation of oligomers of lipidated peptide induced by change in pH. Mol Pharm 2015; 12: 411-419
• 21 Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited. Biopharm Drug Dispos 2010; 31: 253-263
• 22 Mordenti J, Chen SA, Moore JA. et al. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8: 1351-1359
• 23 Mahmood I. Interspecies scaling of protein drugs: Prediction of clearance from animals to humans. J Pharm Sci 2004; 93: 177-185